No hantavirus vaccine is positioned for approval or availability by the end of 2026, as all active candidates remain in preclinical or early-phase clinical development. Promising mRNA platforms, including single-dose formulations tested in hamster models against Andes virus and collaborative efforts by Moderna with Korea University, have shown immunogenicity and protection in rodents but have not entered human trials. DNA and other candidates have completed only Phase 1 safety and immunogenicity studies, with no Phase 3 efficacy trials underway for any strain. The low incidence of hantavirus pulmonary syndrome and hemorrhagic fever with renal syndrome complicates large-scale human testing, while regulatory pathways for rare pathogens require extensive additional data. A recent cruise-ship cluster has heightened visibility and prompted further research funding, yet standard timelines for manufacturing scale-up, safety assessments, and approval exceed the remaining months of 2026 absent an extraordinary acceleration mechanism.